Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Conge

Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.